ValuEngine upgraded shares of Alliqua Biomedical (NASDAQ:ALQA) from a sell rating to a hold rating in a research note issued to investors on Thursday.

Separately, HC Wainwright set a $5.00 price target on Alliqua Biomedical and gave the company a buy rating in a report on Wednesday, January 3rd. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Alliqua Biomedical has a consensus rating of Hold and an average target price of $8.20.

Alliqua Biomedical (ALQA) opened at $1.87 on Thursday. Alliqua Biomedical has a one year low of $1.58 and a one year high of $8.50.

WARNING: This report was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at

Alliqua Biomedical Company Profile

Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Alliqua Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Biomedical and related companies with's FREE daily email newsletter.